Galapagos Scores $275M As IPO Beats Sweetened Terms
Belgium-based Galapagos NV, a venture capital-backed biotech developing two drug candidates with AbbVie Inc., surpassed sweetened terms on Wednesday to rake in $275 million through its U.S. initial public offering and...To view the full article, register now.
Already a subscriber? Click here to view full article